ArticleBioengineering (Basel, Switzerland)2025
Characterization of a Novel POx-Based Adhesive Powder for Obliterating Dead Spaces After Surgery.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Surgical dead spaces are challenging to handle with current preventive methods. Tissue adhesives show promise in obliterating 'dead spaces', but the drawbacks of currently available adhesives prevent them from being used for dead space elimination. An adhesive powder based on N-Hydroxysuccinimide-poly(2-oxazoline), NHS-POx, combines robust adhesive strength in moist environments with favorable biocompatibility and biodegradability, which makes this an interesting candidate for eliminating spaces that remain between tissues after surgery. The current study evaluates the swelling, crosslinking speed, and degradation properties of this novel tissue adhesive. These results were then used to design multiple adhesive variants differing in pH, surfactant addition, and particle size, which were subsequently examined based on their wetting rates, adhesive strength, and durability. The powder displayed minimal swelling and rapid crosslinking properties, by which the latter could be increased by a basic buffer or surfactant addition and reduced by increasing particle size. The wetting rate of the powder increased when a surfactant (Pluronic F68) was added to the mix. The adhesive strength, as measured by tensile and shear strength measurements of different prototypes of the adhesive powder, was significantly better than that of a commercially available fibrin glue. The addition of both buffer and Pluronic F68 led to a breakdown of adhesive force after 14 days of incubation, while the prototype containing neither buffer nor Pluronic F68 still had measurable adhesive force after 14 days of incubation. The current study results display several characteristics of the NHS-POx-based tissue adhesive that are favorable for tissue approximation, preventing the occurrence of dead spaces. The most effective and usable adhesive prototype will be identified in further ex vivo and in vivo animal model studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.